VASTHERA Receives U.S. FDA Clearance to initiate Phase 1 Clinical Trial of Pulmonary Arterial Hypertension Drug Candidate, VTB-10

Contributed by: Business Wire

Logo

Tags

Health

FDA

Clinical Trials

Research

Science

Pharmaceutical

Biotechnology

VASTHERA Co., Ltd.

More Like This

PR Newswire associated0

Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHT

Vaderis Receives FDA Fast Track Designation for VAD044 for the Treatment of Hereditary Hemorrhagic Telangiectasia

Ferrer Obtains the Distribution Rights for Treprostinil Inhalation Solution Including the Potential Indications for Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF)

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

Pulnovo Medical Announces First Enrollment in Portugal for Global Clinical Study of PADN Technology in Treating Pulmonary Hypertension Associated with Left Heart Disease

Pulnovo Medical Announces Joining PHA's (Pulmonary Hypertension Association) Corporate Committee

PR Newswire associated0

Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system granted Health Canada approval

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera